ISAVUCONAZOLE IS A SENSITIVE SUBSTRATE OF CYP3A4. CYP3A4 INHIBITORS OR INDUCERS MAY ALTER THE PLASMA CONCENTRATIONS OF ISAVUCONAZOLE.
COADMINISTRATION OF ISAVUCONAZOLE WITH STRONG CYP3A4 INHIBITORS SUCH AS KETOCONAZOLE, LOPINAVIR OR HIGH DOSE RITONAVIR MAY CAUSE MORE THAN FIVE FOLD INCREASE IN ITS PLASMA LEVELS.
STRONG CYP3A4 INDUCERS SUCH AS RIFAMPIN, CARBAMAZEPINE, ST. JOHN'S WORT, OR LONG ACTING BARBITURATES IS CONTRAINDICATED SINCE IT CAUSES 97% DECREASE IN ITS PLASMA CONCENTRATION.
CYCLOSPORIN & ATORVASTATIN PLASMA CONC. IS INCREASED ON COADMINISTRATION.
CONCOMITANT ADMINISTRATION OF LOPINAVIR/RITONAVIR RESULTED IN DECREASED EXPOSURE OF LOPINAVIR AND RITONAVIR THAT COULD POSSIBLY RESULT IN LOSS OF ANTIVIRAL EFFICACY.
SIROLIMUS, TACROLIMUS, MIDAZOLAM, MYCOPHENOLATE MOFETIL & DIGOXIN PLASMA CONC. IS INCREASED ON COADMINISTRATION. BUPROPION SERUM CONC. IS DECREASED ON CO-ADMINISTRATION.